Dabney: Why rescheduling cannabis isn’t enough

The White House issued an executive order titled “Increasing Medical Marijuana and Cannabidiol Research” directing the Attorney General to complete rulemaking to move cannabis from Schedule I to Schedule III under the Controlled Substances Act, signaling federal acknowledgement of medical use and aiming to accelerate research. While the shift marks a historic tonal change from federal policy, the action relies on a regulatory process and does not immediately end federal prohibition, limiting near-term legal or market effects for cannabis operators but potentially easing research and future commercial opportunities if implemented.

Analysis

Market structure: Rescheduling rhetoric is a catalyst for US-focused MSOs, banking access, and potential tax relief (280E) that could lift EBITDA margins by 5–15 percentage points for profitable operators once implemented. Immediate winners are scale-enabled US MSOs (Curaleaf, Green Thumb, Cresco) and ancillary suppliers (Scotts/SMG); losers are overvalued Canadian LPs (Canopy/CGC, Tilray/TLRY) that rely on Canada-centered growth narratives. Cross-asset: expect short-term equity volatility, tightening credit spreads for higher-quality MSOs, modest FX flows into CAD if Canadian names underperform, and limited commodity impact.

Risk assessment: Short-term (days–weeks) risks are headline-driven volatility and knee-jerk rallies; medium-term (3–12 months) risk is slow rulemaking — estimate 30–50% chance of final rescheduling within 12 months — and legal challenges; long-term (1–3 years) risks include Congress/IRS pushback on 280E and tougher GMP/pharma standards raising capex. Tail risks: full reclassification followed by rapid pharma consolidation could destroy pure-play cultivator margins; opposite tail (policy reversal) would trigger >40% drawdowns in euphoric names.

Trade implications: Favor concentrated, time-boxed long exposure to top US MSOs (GTBIF, CURLF, CRLBF) and an ETF hedge (MJ) via call spreads 3–6 months out to capture regulatory progress while capping premium. Pair: long GTBIF (3% portfolio) / short CGC (1.5%) dollar-neutral to arbitrage US vs Canada repricing. Reduce existing positions in TLRY/CGC by 40–60% and avoid long-term unsecured debt of smaller MSOs until 280E clarity.

Contrarian angles: Consensus assumes rescheduling equals immediate mass-market disintermediation; missing is that Schedule III can accelerate pharmaceuticalization — higher compliance costs and IP-driven products that favor big pharma (MRK/PFE) over plant cultivators. Reaction is likely partly overdone in equities (expect 20–35% mean reversion if no rule within 6 months). Historical parallel: partial liberalizations (alcohol prohibition repeal) created category winners but also consolidated incumbents; expect similar consolidation here.

Key Decisions for Investors

• Establish a 2–3% long position split equally between Green Thumb (GTBIF) and Curaleaf (CURLF) within 10 trading days to capture re-rating if DOJ issues a proposed/ interim final rule within 90 days; if a final rule appears within 12 months, scale to 5–6% over 3 months.
• Initiate a dollar-neutral pair: long GTBIF (3% portfolio) / short Canopy Growth (CGC) (1.5%) to exploit likely stronger US uplift; close or rebalance if spread compresses by 50% or if CGC outperforms GTBIF by 20% intra-quarter.
• Buy 3–6 month call spreads on MJ (ETF) using 20–30% OTM strikes, allocating 0.5–1% of portfolio to capture policy progress with defined downside; roll or close if implied volatility rises >40% above the 90-day historical average.
• Reduce exposure to TLRY and CGC equity holdings by 40–60% immediately; redeploy proceeds into the US MSO longs or cash unless company-specific catalysts (US foothold, positive 280E guidance) appear within 60 days.
• If DOJ/AG publishes a proposed rule within 90 days that clearly moves cannabis to Schedule III, add a 1–2% position in large-cap pharma (e.g., MRK or PFE) to hedge potential pharma consolidation; exit if rulemaking stalls beyond 12 months or if congressional language blocks 280E relief.